Literature DB >> 22290259

Immunotherapy for the treatment of glioblastoma.

Alissa A Thomas1, Marc S Ernstoff, Camilo E Fadul.   

Abstract

Glioblastoma, the most aggressive primary brain tumor, thrives in a microenvironment of relative immunosuppression within the relatively immune-privileged central nervous system. Despite treatments with surgery, radiation therapy, and chemotherapy, prognosis remains poor. The recent success of immunotherapy in the treatment of other cancers has renewed interest in vaccine therapy for the treatment of gliomas. In this article, we outline various immunotherapeutic strategies, review recent clinical trials data, and discuss the future of vaccine therapy for glioblastoma.

Entities:  

Mesh：

Year:  2012        PMID： 22290259      PMCID： PMC3269657          DOI： 10.1097/PPO.0b013e3182431a73

Source DB:  PubMed          Journal:  Cancer J        ISSN： 1528-9117            Impact factor:   3.360


  91 in total

1.  Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma.

Authors:  John H Sampson; Amy B Heimberger; Gary E Archer; Kenneth D Aldape; Allan H Friedman; Henry S Friedman; Mark R Gilbert; James E Herndon; Roger E McLendon; Duane A Mitchell; David A Reardon; Raymond Sawaya; Robert J Schmittling; Weiming Shi; James J Vredenburgh; Darell D Bigner
Journal:  J Clin Oncol       Date:  2010-10-04       Impact factor: 44.544

Review 2.  Trafficking of immune cells in the central nervous system.

Authors:  Emma H Wilson; Wolfgang Weninger; Christopher A Hunter
Journal:  J Clin Invest       Date:  2010-05-03       Impact factor: 14.808

3.  Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group.

Authors:  Patrick Y Wen; David R Macdonald; David A Reardon; Timothy F Cloughesy; A Gregory Sorensen; Evanthia Galanis; John Degroot; Wolfgang Wick; Mark R Gilbert; Andrew B Lassman; Christina Tsien; Tom Mikkelsen; Eric T Wong; Marc C Chamberlain; Roger Stupp; Kathleen R Lamborn; Michael A Vogelbaum; Martin J van den Bent; Susan M Chang
Journal:  J Clin Oncol       Date:  2010-03-15       Impact factor: 44.544

Review 4.  Immunotherapy coming of age: what will it take to make it standard of care for glioblastoma?

Authors:  Amy B Heimberger; John H Sampson
Journal:  Neuro Oncol       Date:  2010-12-10       Impact factor: 12.300

5.  Integration of autologous dendritic cell-based immunotherapy in the primary treatment for patients with newly diagnosed glioblastoma multiforme: a pilot study.

Authors:  Hilko Ardon; Stefaan Van Gool; Isabel Spencer Lopes; Wim Maes; Raf Sciot; Guido Wilms; Philippe Demaerel; Patricia Bijttebier; Laurence Claes; Jan Goffin; Frank Van Calenbergh; Steven De Vleeschouwer
Journal:  J Neurooncol       Date:  2010-02-10       Impact factor: 4.130

Review 6.  Immunologic biomarkers as correlates of clinical response to cancer immunotherapy.

Authors:  Mary L Disis
Journal:  Cancer Immunol Immunother       Date:  2011-01-08       Impact factor: 6.968

7.  Autologous tumor cell vaccination plus infusion of GM-CSF by a programmable pump in the treatment of recurrent malignant gliomas.

Authors:  Anne Clavreul; Nicole Piard; Jean-Yves Tanguy; Eric Gamelin; Marie-Christine Rousselet; Pierre Leynia; Philippe Menei
Journal:  J Clin Neurosci       Date:  2010-05-13       Impact factor: 1.961

8.  Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma.

Authors:  Hideho Okada; Pawel Kalinski; Ryo Ueda; Aki Hoji; Gary Kohanbash; Teresa E Donegan; Arlan H Mintz; Johnathan A Engh; David L Bartlett; Charles K Brown; Herbert Zeh; Matthew P Holtzman; Todd A Reinhart; Theresa L Whiteside; Lisa H Butterfield; Ronald L Hamilton; Douglas M Potter; Ian F Pollack; Andres M Salazar; Frank S Lieberman
Journal:  J Clin Oncol       Date:  2010-12-13       Impact factor: 44.544

9.  Phase I trial of a personalized peptide vaccine for patients positive for human leukocyte antigen--A24 with recurrent or progressive glioblastoma multiforme.

Authors:  Mizuhiko Terasaki; Soichiro Shibui; Yoshitaka Narita; Takamitsu Fujimaki; Tomokazu Aoki; Koji Kajiwara; Yutaka Sawamura; Kaoru Kurisu; Toshihiro Mineta; Akira Yamada; Kyogo Itoh
Journal:  J Clin Oncol       Date:  2010-12-13       Impact factor: 44.544

Review 10.  Overview of cellular immunotherapy for patients with glioblastoma.

Authors:  Elodie Vauleon; Tony Avril; Brigitte Collet; Jean Mosser; Véronique Quillien
Journal:  Clin Dev Immunol       Date:  2010-10-04
View more
  34 in total

Review 1.  Paediatric and adult malignant glioma: close relatives or distant cousins?

Authors:  Chris Jones; Lara Perryman; Darren Hargrave
Journal:  Nat Rev Clin Oncol       Date:  2012-05-29       Impact factor: 66.675

Review 2.  The Gut-Brain Axis, Paving the Way to Brain Cancer.

Authors:  Ruty Mehrian-Shai; Juergen K V Reichardt; Curtis C Harris; Amos Toren
Journal:  Trends Cancer       Date:  2019-03-16

3.  MiR-138 exerts anti-glioma efficacy by targeting immune checkpoints.

Authors:  Jun Wei; Edjah K Nduom; Ling-Yuan Kong; Yuuri Hashimoto; Shuo Xu; Konrad Gabrusiewicz; Xiaoyang Ling; Neal Huang; Wei Qiao; Shouhao Zhou; Cristina Ivan; Greg N Fuller; Mark R Gilbert; Willem Overwijk; George A Calin; Amy B Heimberger
Journal:  Neuro Oncol       Date:  2015-12-11       Impact factor: 12.300

4.  Recombinant adenovirus expressing a dendritic cell-targeted melanoma surface antigen for tumor-specific immunotherapy in melanoma mice model.

Authors:  Li-Li Guo; Gang-Cheng Wang; Peng-Jie Li; Cui-Mei Wang; Lin-Bo Liu
Journal:  Exp Ther Med       Date:  2018-04-23       Impact factor: 2.447

Review 5.  Pediatric diffuse intrinsic pontine glioma: can optimism replace pessimism?

Authors:  Darren Hargrave
Journal:  CNS Oncol       Date:  2012-11

Review 6.  Severity, etiology and possible consequences of treatment-related lymphopenia in patients with newly diagnosed high-grade gliomas.

Authors:  Susannah Yovino; Stuart A Grossman
Journal:  CNS Oncol       Date:  2012-11

7.  Overexpression of p53 delivered using recombinant NDV induces apoptosis in glioma cells by regulating the apoptotic signaling pathway.

Authors:  Xiaoyong Fan; Hongzhen Lu; Youqiang Cui; Xianzeng Hou; Chuanjiang Huang; Guangcun Liu
Journal:  Exp Ther Med       Date:  2018-03-08       Impact factor: 2.447

8.  PD-L1 expression and prognostic impact in glioblastoma.

Authors:  Edjah K Nduom; Jun Wei; Nasser K Yaghi; Neal Huang; Ling-Yuan Kong; Konrad Gabrusiewicz; Xiaoyang Ling; Shouhao Zhou; Cristina Ivan; Jie Qing Chen; Jared K Burks; Greg N Fuller; George A Calin; Charles A Conrad; Caitlin Creasy; Krit Ritthipichai; Laszlo Radvanyi; Amy B Heimberger
Journal:  Neuro Oncol       Date:  2015-08-30       Impact factor: 12.300

Review 9.  Vaccine-based immunotherapy for glioblastoma.

Authors:  Alissa A Thomas; Jan L Fisher; Marc S Ernstoff; Camilo E Fadul
Journal:  CNS Oncol       Date:  2013-07

10.  Dendritic cell vaccine and cytokine-induced killer cell therapy for the treatment of advanced non-small cell lung cancer.

Authors:  Lihong Zhang; Xuejing Yang; Zhen Sun; Jiali Li; Hui Zhu; Jing Li; Yan Pang
Journal:  Oncol Lett       Date:  2016-02-24       Impact factor: 2.967
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.